Affordable Access

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.

Authors
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Volume
16
Issue
10
Pages
1695–1701
Identifiers
PMID: 16012180
Source
Medline
License
Unknown

Abstract

rh-endostatin was safely administered both by continuous infusion and by twice daily subcutaneous injections up to 120 mg/m(2)/day. Predictable pK was seen in this dose range and the target endostatin levels were reached from 60 mg/m(2)/day and above.

Statistics

Seen <100 times